Drug development in the light of translational science: Shine or shade?

Drug Discovery Today

Volumn 16, Issue 23-24, 2011, Pages 1076-1083

  Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TORCETRAPIB; VARENICLINE;

ALGORITHM; BIOMEDICINE; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; HUMAN; MEDICAL RESEARCH; NONHUMAN; REPRODUCIBILITY; REVIEW; STANDARD; TRANSLATIONAL RESEARCH;

ANIMALS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 82255179546     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.07.008     Document Type: Review

References (44)

1. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat. Rev. Drug Discov. 2 2003 566 580 (Pubitemid 37361748)
2. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715 (Pubitemid 39173511)
3. E.F. Schmid, and D.A. Smith Pharmaceutical R&D in the spotlight: why is there still unmet medical need? Drug Discov. Today 12 2007 998 1006 (Pubitemid 350186131)
4. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
5. M. Wehling Principles of Translational Science in Medicine: From Bench to Bedside 2010 Cambridge University Press
6. C. Bernard Introduction l'Étude de la Médecine Expérimentale 1865 Baillire
7. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
8. T.E. Stinchcombe, and T.E. Socinski Current treatments for advanced stage non-small cell lung cancer Proc. Am. Thorac. Soc. 6 2009 233 241
9. P. Littlejohns 10 years of NICE: still growing and still controversial Lancet Oncol. 10 2009 417 424
10. G.J. Burckart Qualification of biomarkers for drug development in organ transplantation Am. J. Transplant. 8 2008 267 270
11. F. Dieterle Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium Nat. Biotechnol. 28 2010 455 462
12. O.B. Sheynin On the history of medical statistics Arch. Hist. Exact. Sci. 26 1982 241 286
13. M. Wehling Translational medicine: can it really facilitate the transition of research 'from bench to bedside'? Eur. J. Clin. Pharmacol. 62 2006 91 95
14. M. Wehling Translational science in medicine; implications for the pharmaceutical industry Int. J. Pharm. Med. 20 2006 303 310 (Pubitemid 44885763)
15. M. Wehling Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. 8 2009 541 546
16. P.J. Barter Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 357 2007 2109 2122 (Pubitemid 350146106)
17. S.E. Nissen Effect of torcetrapib on the progression of coronary atherosclerosis N. Engl. J. Med. 356 2007 1304 1316 (Pubitemid 46513296)
18. E. Nikkila Studies on the lipid-protein relationship in normal and pathological sera and the effect of heparin on serum lipoproteins Scand. J. Clin. Lab. Invest 5 Suppl. 8 1953 9 100
19. T. Gordon High-density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am. J. Med. 62 1977 707 714 (Pubitemid 8110784)
20. B.G. Brown Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N. Engl. J. Med. 345 2001 1583 1592 (Pubitemid 33126837)
21. A.J. Taylor Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517 (Pubitemid 39612564)
22. M.H. Frick Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N. Engl. J. Med. 317 1987 1237 1245 (Pubitemid 17147964)
23. M.E. Brousseau Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N. Engl. J. Med. 350 2004 1505 1515 (Pubitemid 38477775)
24. L.A. Morehouse Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand white rabbits J. Lipid Res. 48 2007 1263 1272 (Pubitemid 47312028)
25. P.J. Kappelle Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion Cardiovasc. Ther. 2010 10.1111/j.1755-5922.2010.00201.x
26. C.P. Cannon Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 363 2010 2406 2415
27. R.L. Papke, and S.F. Heinemann Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit Mol. Pharmacol. 45 1994 142 149 (Pubitemid 24042293)
28. Y.E. Slater Halogenated cytosine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes Neuropharmacology 44 2003 503 515 (Pubitemid 36293982)
29. J.F. Etter Cytisine for smoking cessation: a literature review and a meta-analysis Arch. Intern. Med. 166 2006 1553 1559
30. C. Reavill Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline Neuropharmacology 29 1990 619 624 (Pubitemid 20225074)
31. D.H. Malin Nicotine dependence: studies with a laboratory model Pharmacol. Biochem. Behav. 70 2001 551 559 (Pubitemid 34131648)
32. C. Léna, and J.P. Changeux The role of beta 2-subunit-containing nicotinic acetylcholine receptors in the brain explored with a mutant mouse Ann. N. Y. Acad. Sci. 868 1999 611 616 (Pubitemid 29281172)
33. J.R. Hughes, and D. Hatsukami Signs and symptoms of tobacco withdrawal Arch. Gen. Psychiatry 43 1986 289 294 (Pubitemid 16052281)
34. L.S. Cox Evaluation of the brief questionnaire of smoking urges (QSU-Brief) in laboratory and clinical settings Nicotine Tob. Res. 3 2001 7 16 (Pubitemid 32611534)
35. J.T. Hays Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial Ann. Intern. Med. 135 2001 423 433 (Pubitemid 32845867)
36. J.D. Killen Extended treatment with bupropion SR for cigarette smoking cessation J. Consult. Clin. Psychol. 74 2006 286 294 (Pubitemid 43807361)
37. C. Jiménez-Ruiz Varenicline: a novel pharmacotherapy for smoking cessation Drugs 69 2009 1319 1338
38. A.V. Finn Concept of vulnerable/unstable plaque Arterioscler. Thromb. Vasc. Biol. 30 2010 1282 1292
39. V. Fuster, and T.P. Vahl The role of noninvasive imaging in promoting cardiovascular health J. Nucl. Cardiol. 17 2010 781 790
40. V. Fuster Early identification of atherosclerotic disease by noninvasive imaging Nat. Rev. Cardiol. 7 2010 327 333
41. K.R. Sipido Identifying needs and opportunities for advancing translational research in cardiovascular disease Cardiovasc. Res. 83 2009 425 435
42. K. Hirano Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity Arterioscler. Thromb. Vasc. Biol. 17 1997 1053 1059 (Pubitemid 27260323)
43. M.H. Davidson Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels J. Am. Coll. Cardiol. 48 2006 1774 1781 (Pubitemid 44648633)
44. J.M. McKenney Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin J. Am. Coll. Cardiol. 48 2006 1782 1790 (Pubitemid 44648632)